All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Update: FDA ODAC delays approval of selinexor until more data are available
The U.S. Food and Drug Administration (FDA) oncologic drugs advisory committee (ODAC) yesterday voted 8 to 5 in favor of delaying the accelerated approval of selinexor until more data are available from the phase III BOSTON trial (NCT03110562).1
The draft voting question for the committee centered around whether approval of selinexor should be postponed until the randomized phase III trial results are available. Those voting in favor of the delay questioned whether the data supported the risk-benefit profile of the drug.
Considerations that arose during the ODAC meeting included:
- The STORM study, which the application was based on, was a combination trial
- The previous phase I study did not demonstrate that selinexor exhibited strong single-agent activity meaning the benefit of selinexor is difficult to ascertain
- Significant toxicity was reported during the study that resulted in patient mortality
The FDA will now await the results of the BOSTON trial which is an open-label, phase III study in patients with relapsed/refractory multiple myeloma, evaluating whether the addition of selinexor to bortezomib and dexamethasone therapy is superior to bortezomib and dexamethasone alone.
Background2
Selinexor is an XPO1 inhibitor indicated in the treatment of penta-refractory multiple myeloma (MM). The application is based on part 2 of the STORM study (KCP-330-012) which was a multicentre, open-label, single arm, phase IIb trial investigating the efficacy and safety of treatment with selinexor (80mg orally, twice weekly) and dexamethasone (20mg orally twice weekly) in 123 enrolled patients.
- Efficacy (N = 122)
- Overall response rate: 25.4% (95% CI, 18.0–34.1)
- Median duration of response in responders (N = 31): 4.4 months (0.8–9.0)
- Safety (N = 123)
- Mortality within 30 days of treatment: N = 23
- Causes of mortality: disease progression (N = 13), fatal treatment-emergent adverse events (TEAE; N = 10)
- TEAE any grade: 100%
- TEAE grade ≥3: 93.5%
- TEAE was the cause of study discontinuation in 28.5% of patients
References